BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Layoffs in California: Amgen to Slash 200 R&D Jobs, Genentech to Cut 130

  It’s not uncommon for companies to announce layoffs in the final months of the year.

  November 6, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  BioMidwest

  Gates and His Rich Buddies Back Exicure’s $11.2M Funding Round

  Exicure announced it had closed on $11.2M in private financing.

  November 6, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva

  Shares of Teva are up more than 5 percent this morning after Israeli media reported billionaire businessman Len Blavatnik is considering taking a large stock position in the pharma giant.

  November 6, 2017

   · 

  2 min read

   · 

  Alex Keown
• Business

  Guangzhou Pharma May Form China Generics JV With Teva Pharma

  November 6, 2017

   · 

  1 min read
• 

  Policy

  TherapeuticsMD Soars on Plans to Resubmit TX-004HR NDA Without New Pre-Approval Study

  Shares of TherapeuticsMD have shot up more than 51 percent in morning trading after the FDA reversed course on its rejection of that company’s vaginal pain medication.

  November 6, 2017

   · 

  2 min read

   · 

  Alex Keown
• Business

  Enesi Pharma Appoints New International Scientific Advisory Board

  The SAB includes experts in vaccines and preventative health from leading academic/ research and international health organisations in the US and Europe.

  November 6, 2017

   · 

  3 min read
• 

  Business

  Johnson & Johnson Breaks Ground on New Facility in China

  The new Ethicon factory has attracted a total investment of $180 million.

  November 6, 2017

   · 

  1 min read
• 

  FDA

  FDA Approves Genentech’s Zelboraf, the First-Ever Drug to Treat Specific Rare Blood Disease

  People diagnosed with the rare blood disorder known as Erdheim-Chester disease have a new treatment option.

  November 6, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Former ArthroCare CEO Draws 20 Year Prison Sentence

  Baker and ex-ArthroCare CFO Michael Gluk were convicted in June 2014 on charges that they ran a scheme to generate false revenue numbers

  November 6, 2017

   · 

  1 min read
• 

  Business

  The Battle Between Two $1B+ Biotech Unicorns

  Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics.

  November 6, 2017

   · 

  2 min read

   · 

  Mark Terry